Research Evidence Library
One profile per compound, built the same way every time: what's actually been studied, at what evidence stage, with real sources — and just as importantly, what the evidence does not establish.
Evidence stages are not a score
Every profile is placed on this scale based on what's actually been published — not on whether we think it works.
A "Preclinical Only" label means exactly that — it does not mean a compound is ineffective, and an "Established Clinical Evidence" label for one specific indication doesn't mean a compound is broadly proven for everything it's discussed for. These labels describe how much has been published and at what level, not how well something works. Absence of high-quality evidence is not evidence of absence — it means nobody has published the research yet, which is a different thing entirely.
Compound profiles
BPC-157
A large, decades-long preclinical literature on tissue repair — and a human evidence base that hasn't caught up to it. One retrospective human study identified; two registered trials, neither showing completed published results yet.
Tesamorelin
FDA-approved in the US for one specific indication, based on real Phase III trial data — and explicitly not authorised in the UK or EU, after a withdrawn EMA application. A case study in why "approved" isn't one global fact.
Quality over quantity — each new profile goes through the same verification process as the two above before it's published.